These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 22844983)
1. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Schmitt J; Spuls P; Boers M; Thomas K; Chalmers J; Roekevisch E; Schram M; Allsopp R; Aoki V; Apfelbacher C; Bruijnzeel-Koomen C; Bruin-Weller M; Charman C; Cohen A; Dohil M; Flohr C; Furue M; Gieler U; Hooft L; Humphreys R; Ishii HA; Katayama I; Kouwenhoven W; Langan S; Lewis-Jones S; Merhand S; Murota H; Murrell DF; Nankervis H; Ohya Y; Oranje A; Otsuka H; Paul C; Rosenbluth Y; Saeki H; Schuttelaar ML; Stalder JF; Svensson A; Takaoka R; Wahlgren CF; Weidinger S; Wollenberg A; Williams H Allergy; 2012 Sep; 67(9):1111-7. PubMed ID: 22844983 [TBL] [Abstract][Full Text] [Related]
2. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N Br J Dermatol; 2021 Jul; 185(1):139-146. PubMed ID: 33393074 [TBL] [Abstract][Full Text] [Related]
3. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Schmitt J; Spuls PI; Thomas KS; Simpson E; Furue M; Deckert S; Dohil M; Apfelbacher C; Singh JA; Chalmers J; Williams HC; J Allergy Clin Immunol; 2014 Oct; 134(4):800-7. PubMed ID: 25282560 [TBL] [Abstract][Full Text] [Related]
4. Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting report. Jacobson ME; Thomas KS; Apfelbacher CJ; Leshem YA; Williams HC; Gerbens LAA; Spuls PI; Schmitt J; Howells L; Katoh N; Simpson EL; Arch Dermatol Res; 2023 Nov; 315(9):2617-2622. PubMed ID: 37432466 [TBL] [Abstract][Full Text] [Related]
5. Reaching clinically relevant outcome measures for new pharmacotherapy and immunotherapy of atopic eczema. Chalmers J; Deckert S; Schmitt J; Curr Opin Allergy Clin Immunol; 2015 Jun; 15(3):227-33. PubMed ID: 26153875 [TBL] [Abstract][Full Text] [Related]
7. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N Br J Dermatol; 2020 Nov; ():. PubMed ID: 33179283 [TBL] [Abstract][Full Text] [Related]
8. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. Leshem YA; Chalmers JR; Apfelbacher C; Furue M; Gerbens LAA; Prinsen CAC; Schmitt J; Spuls PI; Thomas KS; Williams HC; Simpson EL; J Am Acad Dermatol; 2020 May; 82(5):1181-1186. PubMed ID: 31926221 [TBL] [Abstract][Full Text] [Related]
10. The HOME Core outcome set for clinical trials of atopic dermatitis. Williams HC; Schmitt J; Thomas KS; Spuls PI; Simpson EL; Apfelbacher CJ; Chalmers JR; Furue M; Katoh N; Gerbens LAA; Leshem YA; Howells L; Singh JA; Boers M; J Allergy Clin Immunol; 2022 Jun; 149(6):1899-1911. PubMed ID: 35351441 [TBL] [Abstract][Full Text] [Related]
11. Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative. Leshem YA; Chalmers JR; Apfelbacher C; Katoh N; Gerbens LAA; Schmitt J; Spuls PI; Thomas KS; Howells L; Williams HC; Simpson EL; JAMA Dermatol; 2022 Dec; 158(12):1429-1435. PubMed ID: 36223090 [TBL] [Abstract][Full Text] [Related]
12. IDQoL, CDLQI and the 45-item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan: a group discussion study. Gabes M; Apfelbacher C; J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):458-463. PubMed ID: 32745352 [TBL] [Abstract][Full Text] [Related]
13. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Chalmers JR; Schmitt J; Apfelbacher C; Dohil M; Eichenfield LF; Simpson EL; Singh J; Spuls P; Thomas KS; Admani S; Aoki V; Ardeleanu M; Barbarot S; Berger T; Bergman JN; Block J; Borok N; Burton T; Chamlin SL; Deckert S; DeKlotz CC; Graff LB; Hanifin JM; Hebert AA; Humphreys R; Katoh N; Kisa RM; Margolis DJ; Merhand S; Minnillo R; Mizutani H; Nankervis H; Ohya Y; Rodgers P; Schram ME; Stalder JF; Svensson A; Takaoka R; Teper A; Tom WL; von Kobyletzki L; Weisshaar E; Zelt S; Williams HC Br J Dermatol; 2014 Dec; 171(6):1318-25. PubMed ID: 24980543 [TBL] [Abstract][Full Text] [Related]